Shi-Yong Sun, PhD

Research Program

Cell and Molecular Biology
Phone Number

404-778-2170
Email Address

ssun@emory.edu

Biography

A Georgia Cancer Coalition Distinguished Cancer Scholar, Shi-Yong Sun, PhD, is a tenured professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Sun started his faculty career in 1999 and joined Emory in 2003.

Dr. Sun is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute.

Education

Dr. Sun earned his PhD in cancer pharmacology at Peking Union Medical College/Chinese Academy of Medical Sciences in China in 1990 and received his postdoctoral training in cancer biology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Professional Memberships

Dr. Sun is an active member of the American Association for Cancer Research.

Research

The long-term goal of Dr. Sun's lab is to identify and develop novel and efficacious therapeutic agents or regimens to treat cancer through fully understanding the biology of cancer, particularly pathways that support the survival and growth of cancer cells. His lab primarily focuses on studying regulation of death receptors, particularly TRAIL receptors, by small cancer therapeutic molecules and their implications in drug-induced apoptosis and cancer therapy. His lab is also interested in Akt/mTOR signaling and in targeting this signaling pathway for cancer therapy.

Grants

View Grants

Grant Number	Title
1R01CA245386-01A1	c-Myc modulation and its implications in EGFR-targeted cancer therapy
1R01CA284386-01A1	Targeting hTERT/telomerase for managing acquired resistance to third generation EGFR-TKIs in lung cancer
5R01CA223220-06	Modulation of death receptor 4 in EGFR-targeted cancer therapy
5R01CA245386-02	c-Myc modulation and its implications in EGFR-targeted cancer therapy
5R01CA245386-03	c-Myc modulation and its implications in EGFR-targeted cancer therapy
5R01CA245386-04	c-Myc modulation and its implications in EGFR-targeted cancer therapy
5R01CA245386-05	c-Myc modulation and its implications in EGFR-targeted cancer therapy

Publications

Dr. Sun is on the editorial boards of a number of cancer-related scientific journals and has published extensively in prominent peer-reviewed journals.

Title/Journal	Authors	Publication Date
Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells. Oncogene	YT Oh, Z Chen, D Wang, SS Ramalingam, SY Sun	04/17/2025
Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer. Cancers	G Zhang, A Pannucci, AA Ivanov, J Switchenko, SY Sun, GL Sica, Z Liu, Y Huang, JC Schmitz, TK Owonikoko	01/28/2025
Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981. iScience	R Sharma, S Sharma, P Shriwas, L Mehta, AH Vu, JK Mouw, J Koo, C Huang, VY Matsuk, C Tucker-Burden, G Joseph, M Behera, SY Sun, MA Roy, M Gilbert-Ross, T Leal, AI Marcus, M Shanmugam	11/15/2024
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. The Journal of experimental medicine	Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun	11/04/2024
Is tumor microenvironment important for targeted therapy in lung cancer? Cancer letters	SY Sun	11/01/2024
Spatially resolved subcellular protein-protein interactomics in drug-perturbed lung-cancer cultures and tissues. Nature biomedical engineering	S Cai, T Hu, A Venkataraman, FG Rivera Moctezuma, E Ozturk, N Zhang, M Wang, T Zvidzai, S Das, A Pillai, F Schneider, SS Ramalingam, YT Oh, SY Sun, AF Coskun	10/30/2024
Graph-Based Spatial Proximity of Super-Resolved Protein-Protein Interactions Predicts Cancer Drug Responses in Single Cells. Cellular and molecular bioengineering	N Zhang, S Cai, M Wang, T Hu, F Schneider, SY Sun, AF Coskun	10/01/2024
SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9. FASEB journal : official publication of the Federation of American Societies for Experimental Biology	L Wang, H Yang, C Wang, M Wang, J Huang, T Nyunt, C Osorio, SY Sun, M Pacifici, V Lefebvre, DC Moore, S Wang, W Yang	09/15/2024
Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany)	Z Chen, KA Vallega, VK Boda, Z Quan, D Wang, S Fan, Q Wang, SS Ramalingam, W Li, SY Sun	09/01/2024
Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges. Translational cancer research	C Su, SY Sun	08/31/2024
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. The Journal of clinical investigation	Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun	03/07/2024
ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression. Neoplasia (New York, N.Y.)	W Zhao, D Yu, Y Zhai, SY Sun	08/01/2023
Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors. Chinese medical journal pulmonary and critical care medicine	SY Sun	03/01/2023
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. Cancer gene therapy	Y Deng, G Ma, KA Vallega, D Wang, M Wang, C Wang, S Wang, SS Ramalingam, SY Sun	11/01/2022
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. Cancer gene therapy	Y Deng, G Ma, KA Vallega, D Wang, M Wang, C Wang, S Wang, SS Ramalingam, SY Sun	11/01/2022
Therapeutic potential of the novel Bcl-2/Bcl-X_L dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer. Molecular carcinogenesis	L Qian, KA Vallega, W Yao, D Wang, Y Zhai, X He, SY Sun	11/01/2022
Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors. Frontiers of medicine	SY Sun	10/01/2022
Multiplexed protein profiling reveals spatial subcellular signaling networks. iScience	S Cai, T Hu, M Venkatesan, M Allam, F Schneider, SS Ramalingam, SY Sun, AF Coskun	09/16/2022
Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X_L dual inhibitor that induces Bax-dependent apoptosis. Neoplasia (New York, N.Y.)	W Yao, L Bai, S Wang, Y Zhai, SY Sun	07/01/2022
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. Oncogene	G Ma, Y Deng, L Qian, KA Vallega, G Zhang, X Deng, TK Owonikoko, SS Ramalingam, DD Fang, Y Zhai, SY Sun	03/01/2022
The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells. American journal of cancer research	C Liu, L Qian, KA Vallega, G Ma, D Zong, L Chen, S Wang, SR Ramalingam, Z Qin, SY Sun	01/01/2022
Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations. Frontiers in oncology	C Su, SY Sun	01/01/2022
The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. Pharmacological research	Z Chen, KA Vallega, H Chen, J Zhou, SS Ramalingam, SY Sun	01/01/2022
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene	Z Chen, D Yu, TK Owonikoko, SS Ramalingam, SY Sun	12/01/2021
Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. Cancer letters	W Zhao, D Yu, Z Chen, W Yao, J Yang, SS Ramalingam, SY Sun	10/28/2021
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular cancer research : MCR	G Qian, J Guo, KA Vallega, C Hu, Z Chen, Y Deng, Q Wang, S Fan, SS Ramalingam, TK Owonikoko, W Wei, SY Sun	10/01/2021
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer research	L Zhu, Z Chen, H Zang, S Fan, J Gu, G Zhang, KD Sun, Q Wang, Y He, TK Owonikoko, SS Ramalingam, SY Sun	09/15/2021
Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. Cell reports methods	K Su, Q Yu, R Shen, SY Sun, CS Moreno, X Li, ZS Qin	08/23/2021
MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription. Neoplasia (New York, N.Y.)	L Deng, KA Vallega, S Zhang, P Shi, SY Sun	08/01/2021
Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer. Acta biomaterialia	W Chen, D Yu, SY Sun, F Li	07/15/2021
Rictor, an essential component of mTOR complex 2, undergoes caspase-mediated cleavage during apoptosis induced by multiple stimuli. Apoptosis : an international journal on programmed cell death	L Zhao, L Zhu, YT Oh, G Qian, Z Chen, SY Sun	06/01/2021
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why? Frontiers of medicine	SY Sun	04/01/2021
Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43]. Lung cancer (Amsterdam, Netherlands)	F Liu, Y Liu, X Liu, K Mao, D Zhong, AI Marcus, FR Khuri, SY Sun, Y He, W Zhou	04/01/2021
Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling. Biomolecules	YT Oh, SY Sun	03/26/2021
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	TK Owonikoko, B Dwivedi, Z Chen, C Zhang, B Barwick, V Ernani, G Zhang, M Gilbert-Ross, J Carlisle, FR Khuri, WJ Curran, AA Ivanov, H Fu, S Lonial, SS Ramalingam, SY Sun, EK Waller, GL Sica	03/01/2021
Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget	J Koo, X Wang, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	02/02/2021
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling. Lung Cancer (Auckland, N.Z.)	D Yu, W Zhao, KA Vallega, SY Sun	01/01/2021
Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors. Oncoscience	W Zhao, SY Sun	01/01/2021
Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. Theranostics	S Zhang, Z Chen, P Shi, S Fan, Y He, Q Wang, Y Li, SS Ramalingam, TK Owonikoko, SY Sun	01/01/2021
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. Lung cancer (Amsterdam, Netherlands)	J Gu, L Qian, G Zhang, NP Mahajan, TK Owonikoko, SS Ramalingam, SY Sun	12/01/2020
Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Translational oncology	SY Sun	12/01/2020
Does the natural product, honokiol, have value in the battle against osimertinib resistance? Oncoscience	KA Vallega, SY Sun	09/01/2020
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Cancer	J Gu, W Yao, P Shi, G Zhang, TK Owonikoko, SS Ramalingam, SY Sun	08/15/2020
Correction: Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling. The Journal of biological chemistry	YT Oh, P Yue, W Zhou, JM Balko, EP Black, TK Owonikoko, FR Khuri, SY Sun	06/26/2020
BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1. Cancer research	D Zong, J Gu, GC Cavalcante, W Yao, G Zhang, S Wang, TK Owonikoko, X He, SY Sun	06/01/2020
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Molecular oncology	H Zang, G Qian, J Arbiser, TK Owonikoko, SS Ramalingam, S Fan, SY Sun	04/01/2020
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Cancer	Y Li, H Zang, G Qian, TK Owonikoko, SR Ramalingam, SY Sun	03/15/2020
The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. American journal of cancer research	D Yu, Y Li, KD Sun, J Gu, Z Chen, TK Owonikoko, SS Ramalingam, SY Sun	01/01/2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer	H Zang, G Qian, D Zong, S Fan, TK Owonikoko, SS Ramalingam, SY Sun	01/01/2020
A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer. Theranostics	D Ma, Y Zou, Y Chu, Z Liu, G Liu, J Chu, M Li, J Wang, SY Sun, Z Chang	01/01/2020
Does osimertinib treatment discriminate young patients? Journal of thoracic disease	C Ji, C Zhong, SY Sun	09/01/2019
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation. Oncogene	L Deng, G Qian, S Zhang, H Zheng, S Fan, GB Lesinski, TK Owonikoko, SS Ramalingam, SY Sun	08/01/2019
mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis. Cancer research	S Zhang, G Qian, QQ Zhang, Y Yao, D Wang, ZG Chen, LJ Wang, M Chen, SY Sun	07/15/2019
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. Journal of hematology & oncology	Q Wang, S Yang, K Wang, SY Sun	06/21/2019
The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. Translational oncology	P Shi, S Zhang, L Zhu, G Qian, H Ren, SS Ramalingam, M Chen, SY Sun	05/01/2019
PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma. Oncogenesis	DY Wang, Y Hong, YG Chen, PZ Dong, SY Liu, YR Gao, D Lu, HM Li, T Li, JC Guo, F He, XQ Ren, SY Sun, DD Wu, SF Duan, XY Ji	03/14/2019
Tumour necrosis factor-α-induced protein 8-like 2 is a novel regulator of proliferation, migration, and invasion in human rectal adenocarcinoma cells. Journal of cellular and molecular medicine	DD Wu, SY Liu, YR Gao, D Lu, Y Hong, YG Chen, PZ Dong, DY Wang, T Li, HM Li, ZG Ren, JC Guo, F He, XQ Ren, SY Sun, SF Duan, XY Ji	03/01/2019
Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PloS one	TK Owonikoko, G Zhang, SB Lallani, Z Chen, DE Martinson, FR Khuri, S Lonial, A Marcus, SY Sun	01/01/2019
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. Cancer letters	G Qian, W Yao, S Zhang, R Bajpai, WD Hall, M Shanmugam, S Lonial, SY Sun	10/28/2018
Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands)	F Liu, Y Liu, X Liu, K Mao, D Zhong, AI Marcus, FR Khuri, SY Sun, Y He, W Zhou	09/01/2018
Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function. Oncogene	YT Oh, G Qian, J Deng, SY Sun	06/01/2018
14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia	Y Gu, K Xu, C Torre, M Samur, BG Barwick, M Rupji, J Arora, P Neri, J Kaufman, A Nooka, L Bernal-Mizrachi, P Vertino, SY Sun, J Chen, N Munshi, H Fu, J Kowalski, LH Boise, S Lonial	03/01/2018
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clinical cancer research : an official journal of the American Association for Cancer Research	P Shi, YT Oh, L Deng, G Zhang, G Qian, S Zhang, H Ren, G Wu, B Legendre, E Anderson, SS Ramalingam, TK Owonikoko, M Chen, SY Sun	11/01/2017
The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Scientific reports	YT Oh, L Deng, J Deng, SY Sun	08/14/2017
Inhibition of p70S6K does not mimic the enhancement of Akt phosphorylation by rapamycin. Heliyon	X Wang, P Yue, H Tao, SY Sun	08/01/2017
Modulation of Bax and mTOR for Cancer Therapeutics. Cancer research	R Li, C Ding, J Zhang, M Xie, D Park, Y Ding, G Chen, G Zhang, M Gilbert-Ross, W Zhou, AI Marcus, SY Sun, ZG Chen, GL Sica, SS Ramalingam, AT Magis, H Fu, FR Khuri, WJ Curran, TK Owonikoko, DM Shin, J Zhou, X Deng	06/01/2017
DR5 suppression induces sphingosine-1-phosphate-dependent TRAF2 polyubiquitination, leading to activation of JNK/AP-1 and promotion of cancer cell invasion. Cell communication and signaling : CCS	YT Oh, P Yue, SY Sun	05/08/2017
Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. The Journal of biological chemistry	W Yao, YT Oh, J Deng, P Yue, L Deng, H Huang, W Zhou, SY Sun	10/07/2016
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer letters	P Shi, YT Oh, G Zhang, W Yao, P Yue, Y Li, R Kanteti, J Riehm, R Salgia, TK Owonikoko, SS Ramalingam, M Chen, SY Sun	10/01/2016
Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation. European journal of cancer (Oxford, England : 1990)	G Qian, D Wang, KR Magliocca, Z Hu, S Nannapaneni, S Kim, Z Chen, SY Sun, DM Shin, NF Saba, ZG Chen	09/01/2016
GPRC5A suppresses protein synthesis at the endoplasmic reticulum to prevent radiation-induced lung tumorigenesis. Nature communications	J Wang, AB Farris, K Xu, P Wang, X Zhang, DM Duong, H Yi, HK Shu, SY Sun, Y Wang	06/08/2016
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Scientific reports	YT Oh, J Deng, P Yue, SY Sun	05/25/2016
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. Journal of translational medicine	TK Owonikoko, G Zhang, HS Kim, RM Stinson, R Bechara, C Zhang, Z Chen, NF Saba, S Pakkala, R Pillai, X Deng, SY Sun, MR Rossi, GL Sica, SS Ramalingam, FR Khuri	05/03/2016
Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene	S Li, YT Oh, P Yue, FR Khuri, SY Sun	02/04/2016
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. Oncogene	YT Oh, J Deng, P Yue, TK Owonikoko, FR Khuri, SY Sun	01/28/2016
Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. Oncotarget	YT Oh, P Yue, D Wang, JS Tong, ZG Chen, FR Khuri, SY Sun	12/01/2015
The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. Oncotarget	W Yao, P Yue, FR Khuri, SY Sun	10/27/2015
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer letters	W Yao, P Yue, G Zhang, TK Owonikoko, FR Khuri, SY Sun	08/01/2015
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. Chemistry & biology	L Lang, HF Ding, X Chen, SY Sun, G Liu, C Yan	07/23/2015
The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. Oncotarget	B Han, W Yao, YT Oh, JS Tong, S Li, J Deng, P Yue, FR Khuri, SY Sun	07/10/2015
mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. Molecular and cellular biology	J Koo, P Yue, X Deng, FR Khuri, SY Sun	07/01/2015
Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. The Journal of biological chemistry	J Koo, X Wu, Z Mao, FR Khuri, SY Sun	05/29/2015
GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget	J Koo, X Wang, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	04/20/2015
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, SS Ramalingam, DL Miller, SD Force, GL Sica, J Mendel, Z Chen, A Rogatko, M Tighiouart, RD Harvey, S Kim, NF Saba, A Pickens, M Behera, RW Fu, MR Rossi, WF Auffermann, WE Torres, R Bechara, X Deng, SY Sun, H Fu, AA Gal, FR Khuri	04/15/2015
Cables1 complex couples survival signaling to the cell death machinery. Cancer research	Z Shi, HR Park, Y Du, Z Li, K Cheng, SY Sun, Z Li, H Fu, FR Khuri	01/01/2015
Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer	NF Saba, SJ Hurwitz, K Magliocca, S Kim, TK Owonikoko, D Harvey, SS Ramalingam, Z Chen, J Rogerio, J Mendel, SA Kono, C Lewis, AY Chen, K Higgins, M El-Deiry, T Wadsworth, JJ Beitler, DM Shin, SY Sun, FR Khuri	12/15/2014
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer medicine	TK Owonikoko, G Zhang, X Deng, MR Rossi, JM Switchenko, GH Doho, Z Chen, S Kim, S Strychor, SM Christner, J Beumer, C Li, P Yue, A Chen, GL Sica, SS Ramalingam, J Kowalski, FR Khuri, SY Sun	12/01/2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood	Y Gu, JL Kaufman, L Bernal, C Torre, SM Matulis, RD Harvey, J Chen, SY Sun, LH Boise, S Lonial	05/22/2014
Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. Cancer research	J Koo, P Yue, AA Gal, FR Khuri, SY Sun	05/01/2014
c-FLIP links mTORC2 to apoptosis. Oncoscience	L Zhao, SY Sun	01/01/2014
Prostate cancer metastatic to bone has higher expression of the calcium-sensing receptor (CaSR) than primary prostate cancer. Receptors & clinical investigation	J Feng, X Xu, B Li, E Brown, AB Farris, SY Sun, JJ Yang	01/01/2014
The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. Molecular cancer	H Ren, J Koo, B Guan, P Yue, X Deng, M Chen, FR Khuri, SY Sun	11/22/2013
mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer letters	SY Sun	10/28/2013
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Molecular cancer therapeutics	R Li, Z Hu, SY Sun, ZG Chen, TK Owonikoko, GL Sica, SS Ramalingam, WJ Curran, FR Khuri, X Deng	10/01/2013
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer letters	H Ren, L Zhao, Y Li, P Yue, X Deng, TK Owonikoko, M Chen, FR Khuri, SY Sun	09/28/2013
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. Cancer research	D Park, AT Magis, R Li, TK Owonikoko, GL Sica, SY Sun, SS Ramalingam, FR Khuri, WJ Curran, X Deng	09/01/2013
Blockade of glioma proliferation through allosteric inhibition of JAK2. Science signaling	K He, Q Qi, CB Chan, G Xiao, X Liu, C Tucker-Burden, L Wang, H Mao, X Lu, FE McDonald, H Luo, QW Fan, WA Weiss, SY Sun, DJ Brat, K Ye	07/09/2013
Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. The Journal of biological chemistry	Y Li, X Wang, P Yue, H Tao, SS Ramalingam, TK Owonikoko, X Deng, Y Wang, H Fu, FR Khuri, SY Sun	05/10/2013
Impact of genetic alterations on mTOR-targeted cancer therapy. Chinese journal of cancer	SY Sun	05/01/2013
Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma. Cancer biology & therapy	S Fan, S Müller, ZG Chen, L Pan, M Tighiouart, DM Shin, FR Khuri, SY Sun	04/01/2013
mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer research	L Zhao, P Yue, FR Khuri, SY Sun	03/15/2013
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, TK Owonikoko, M Behera, J Subramanian, NF Saba, SA Kono, AA Gal, G Sica, RD Harvey, Z Chen, CM Klass, DM Shin, H Fu, SY Sun, R Govindan, FR Khuri	03/01/2013
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer letters	H Ren, M Chen, P Yue, H Tao, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	12/28/2012
c-Myc suppression of DNA double-strand break repair. Neoplasia (New York, N.Y.)	Z Li, TK Owonikoko, SY Sun, SS Ramalingam, PW Doetsch, ZQ Xiao, FR Khuri, WJ Curran, X Deng	12/01/2012
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer letters	F Wei, Y Liu, AC Bellail, JJ Olson, SY Sun, G Lu, L Ding, C Yuan, G Wang, C Hao	09/01/2012
NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCι/FAK loop. Cancer letters	J Shen, L Xu, TK Owonikoko, SY Sun, FR Khuri, WJ Curran, X Deng	05/01/2012
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy	DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, K Adeli, L Agholme, M Agnello, P Agostinis, JA Aguirre-Ghiso, HJ Ahn, O Ait-Mohamed, S Ait-Si-Ali, T Akematsu, S Akira, HM Al-Younes, MA Al-Zeer, ML Albert, RL Albin, J Alegre-Abarrategui, MF Aleo, M Alirezaei, A Almasan, M Almonte-Becerril, A Amano, R Amaravadi, S Amarnath, AO Amer, N Andrieu-Abadie, V Anantharam, DK Ann, S Anoopkumar-Dukie, H Aoki, N Apostolova, G Arancia, JP Aris, K Asanuma, NY Asare, H Ashida, V Askanas, DS Askew, P Auberger, M Baba, SK Backues, EH Baehrecke, BA Bahr, XY Bai, Y Bailly, R Baiocchi, G Baldini, W Balduini, A Ballabio, BA Bamber, ET Bampton, G Bánhegyi, CR Bartholomew, DC Bassham, RC Bast, H Batoko, BH Bay, I Beau, DM Béchet, TJ Begley, C Behl, C Behrends, S Bekri, B Bellaire, LJ Bendall, L Benetti, L Berliocchi, H Bernardi, F Bernassola, S Besteiro, I Bhatia-Kissova, X Bi, M Biard-Piechaczyk, JS Blum, LH Boise, P Bonaldo, DL Boone, BC Bornhauser, KR Bortoluci, I Bossis, F Bost, JP Bourquin, P Boya, M Boyer-Guittaut, PV Bozhkov, NR Brady, C Brancolini, A Brech, JE Brenman, A Brennand, EH Bresnick, P Brest, D Bridges, ML Bristol, PS Brookes, EJ Brown, JH Brumell, N Brunetti-Pierri, UT Brunk, DE Bulman, SJ Bultman, G Bultynck, LF Burbulla, W Bursch, JP Butchar, W Buzgariu, SP Bydlowski, K Cadwell, M Cahová, D Cai, J Cai, Q Cai, B Calabretta, J Calvo-Garrido, N Camougrand, M Campanella, J Campos-Salinas, E Candi, L Cao, AB Caplan, SR Carding, SM Cardoso, JS Carew, CR Carlin, V Carmignac, LA Carneiro, S Carra, RA Caruso, G Casari, C Casas, R Castino, E Cebollero, F Cecconi, J Celli, H Chaachouay, HJ Chae, CY Chai, DC Chan, EY Chan, RC Chang, CM Che, CC Chen, GC Chen, GQ Chen, M Chen, Q Chen, SS Chen, W Chen, X Chen, X Chen, X Chen, YG Chen, Y Chen, Y Chen, YJ Chen, Z Chen, A Cheng, CH Cheng, Y Cheng, H Cheong, JH Cheong, S Cherry, R Chess-Williams, ZH Cheung, E Chevet, HL Chiang, R Chiarelli, T Chiba, LS Chin, SH Chiou, FV Chisari, CH Cho, DH Cho, AM Choi, D Choi, KS Choi, ME Choi, S Chouaib, D Choubey, V Choubey, CT Chu, TH Chuang, SH Chueh, T Chun, YJ Chwae, ML Chye, R Ciarcia, MR Ciriolo, MJ Clague, RS Clark, PG Clarke, R Clarke, P Codogno, HA Coller, MI Colombo, S Comincini, M Condello, F Condorelli, MR Cookson, GH Coombs, I Coppens, R Corbalan, P Cossart, P Costelli, S Costes, A Coto-Montes, E Couve, FP Coxon, JM Cregg, JL Crespo, MJ Cronjé, AM Cuervo, JJ Cullen, MJ Czaja, M D'Amelio, A Darfeuille-Michaud, LM Davids, FE Davies, M De Felici, JF de Groot, CA de Haan, L De Martino, A De Milito, V De Tata, J Debnath, A Degterev, B Dehay, LM Delbridge, F Demarchi, YZ Deng, J Dengjel, P Dent, D Denton, V Deretic, SD Desai, RJ Devenish, M Di Gioacchino, G Di Paolo, C Di Pietro, G Díaz-Araya, I Díaz-Laviada, MT Diaz-Meco, J Diaz-Nido, I Dikic, SP Dinesh-Kumar, WX Ding, CW Distelhorst, A Diwan, M Djavaheri-Mergny, S Dokudovskaya, Z Dong, FC Dorsey, V Dosenko, JJ Dowling, S Doxsey, M Dreux, ME Drew, Q Duan, MA Duchosal, K Duff, I Dugail, M Durbeej, M Duszenko, CL Edelstein, AL Edinger, G Egea, L Eichinger, NT Eissa, S Ekmekcioglu, WS El-Deiry, Z Elazar, M Elgendy, LM Ellerby, KE Eng, AM Engelbrecht, S Engelender, J Erenpreisa, R Escalante, A Esclatine, EL Eskelinen, L Espert, V Espina, H Fan, J Fan, QW Fan, Z Fan, S Fang, Y Fang, M Fanto, A Fanzani, T Farkas, JC Farré, M Faure, M Fechheimer, CG Feng, J Feng, Q Feng, Y Feng, L Fésüs, R Feuer, ME Figueiredo-Pereira, GM Fimia, DC Fingar, S Finkbeiner, T Finkel, KD Finley, F Fiorito, EA Fisher, PB Fisher, M Flajolet, ML Florez-McClure, S Florio, EA Fon, F Fornai, F Fortunato, R Fotedar, DH Fowler, HS Fox, R Franco, LB Frankel, M Fransen, JM Fuentes, J Fueyo, J Fujii, K Fujisaki, E Fujita, M Fukuda, RH Furukawa, M Gaestel, P Gailly, M Gajewska, B Galliot, V Galy, S Ganesh, B Ganetzky, IG Ganley, FB Gao, GF Gao, J Gao, L Garcia, G Garcia-Manero, M Garcia-Marcos, M Garmyn, AL Gartel, E Gatti, M Gautel, TR Gawriluk, ME Gegg, J Geng, M Germain, JE Gestwicki, DA Gewirtz, S Ghavami, P Ghosh, AM Giammarioli, AN Giatromanolaki, SB Gibson, RW Gilkerson, ML Ginger, HN Ginsberg, J Golab, MS Goligorsky, P Golstein, C Gomez-Manzano, E Goncu, C Gongora, CD Gonzalez, R Gonzalez, C González-Estévez, RA González-Polo, E Gonzalez-Rey, NV Gorbunov, S Gorski, S Goruppi, RA Gottlieb, D Gozuacik, GE Granato, GD Grant, KN Green, A Gregorc, F Gros, C Grose, TW Grunt, P Gual, JL Guan, KL Guan, SM Guichard, AS Gukovskaya, I Gukovsky, J Gunst, AB Gustafsson, AJ Halayko, AN Hale, SK Halonen, M Hamasaki, F Han, T Han, MK Hancock, M Hansen, H Harada, M Harada, SE Hardt, JW Harper, AL Harris, J Harris, SD Harris, M Hashimoto, JA Haspel, S Hayashi, LA Hazelhurst, C He, YW He, MJ Hébert, KA Heidenreich, MH Helfrich, GV Helgason, EP Henske, B Herman, PK Herman, C Hetz, S Hilfiker, JA Hill, LJ Hocking, P Hofman, TG Hofmann, J Höhfeld, TL Holyoake, MH Hong, DA Hood, GS Hotamisligil, EJ Houwerzijl, M Høyer-Hansen, B Hu, CA Hu, HM Hu, Y Hua, C Huang, J Huang, S Huang, WP Huang, TB Huber, WK Huh, TH Hung, TR Hupp, GM Hur, JB Hurley, SN Hussain, PJ Hussey, JJ Hwang, S Hwang, A Ichihara, S Ilkhanizadeh, K Inoki, T Into, V Iovane, JL Iovanna, NY Ip, Y Isaka, H Ishida, C Isidoro, K Isobe, A Iwasaki, M Izquierdo, Y Izumi, PM Jaakkola, M Jäättelä, GR Jackson, WT Jackson, B Janji, M Jendrach, JH Jeon, EB Jeung, H Jiang, H Jiang, JX Jiang, M Jiang, Q Jiang, X Jiang, X Jiang, A Jiménez, M Jin, S Jin, CO Joe, T Johansen, DE Johnson, GV Johnson, NL Jones, B Joseph, SK Joseph, AM Joubert, G Juhász, L Juillerat-Jeanneret, CH Jung, YK Jung, K Kaarniranta, A Kaasik, T Kabuta, M Kadowaki, K Kagedal, Y Kamada, VO Kaminskyy, HH Kampinga, H Kanamori, C Kang, KB Kang, KI Kang, R Kang, YA Kang, T Kanki, TD Kanneganti, H Kanno, AG Kanthasamy, A Kanthasamy, V Karantza, GP Kaushal, S Kaushik, Y Kawazoe, PY Ke, JH Kehrl, A Kelekar, C Kerkhoff, DH Kessel, H Khalil, JA Kiel, AA Kiger, A Kihara, DR Kim, DH Kim, DH Kim, EK Kim, HR Kim, JS Kim, JH Kim, JC Kim, JK Kim, PK Kim, SW Kim, YS Kim, Y Kim, A Kimchi, AC Kimmelman, JS King, TJ Kinsella, V Kirkin, LA Kirshenbaum, K Kitamoto, K Kitazato, L Klein, WT Klimecki, J Klucken, E Knecht, BC Ko, JC Koch, H Koga, JY Koh, YH Koh, M Koike, M Komatsu, E Kominami, HJ Kong, WJ Kong, VI Korolchuk, Y Kotake, MI Koukourakis, JB Kouri Flores, AL Kovács, C Kraft, D Krainc, H Krämer, C Kretz-Remy, AM Krichevsky, G Kroemer, R Krüger, O Krut, NT Ktistakis, CY Kuan, R Kucharczyk, A Kumar, R Kumar, S Kumar, M Kundu, HJ Kung, T Kurz, HJ Kwon, AR La Spada, F Lafont, T Lamark, J Landry, JD Lane, P Lapaquette, JF Laporte, L László, S Lavandero, JN Lavoie, R Layfield, PA Lazo, W Le, L Le Cam, DJ Ledbetter, AJ Lee, BW Lee, GM Lee, J Lee, JH Lee, M Lee, MS Lee, SH Lee, C Leeuwenburgh, P Legembre, R Legouis, M Lehmann, HY Lei, QY Lei, DA Leib, J Leiro, JJ Lemasters, A Lemoine, MS Lesniak, D Lev, VV Levenson, B Levine, E Levy, F Li, JL Li, L Li, S Li, W Li, XJ Li, YB Li, YP Li, C Liang, Q Liang, YF Liao, PP Liberski, A Lieberman, HJ Lim, KL Lim, K Lim, CF Lin, FC Lin, J Lin, JD Lin, K Lin, WW Lin, WC Lin, YL Lin, R Linden, P Lingor, J Lippincott-Schwartz, MP Lisanti, PB Liton, B Liu, CF Liu, K Liu, L Liu, QA Liu, W Liu, YC Liu, Y Liu, RA Lockshin, CN Lok, S Lonial, B Loos, G Lopez-Berestein, C López-Otín, L Lossi, MT Lotze, P Lőw, B Lu, B Lu, B Lu, Z Lu, F Luciano, NW Lukacs, AH Lund, MA Lynch-Day, Y Ma, F Macian, JP MacKeigan, KF Macleod, F Madeo, L Maiuri, MC Maiuri, D Malagoli, MC Malicdan, W Malorni, N Man, EM Mandelkow, S Manon, I Manov, K Mao, X Mao, Z Mao, P Marambaud, D Marazziti, YL Marcel, K Marchbank, P Marchetti, SJ Marciniak, M Marcondes, M Mardi, G Marfe, G Mariño, M Markaki, MR Marten, SJ Martin, C Martinand-Mari, W Martinet, M Martinez-Vicente, M Masini, P Matarrese, S Matsuo, R Matteoni, A Mayer, NM Mazure, DJ McConkey, MJ McConnell, C McDermott, C McDonald, GM McInerney, SL McKenna, B McLaughlin, PJ McLean, CR McMaster, GA McQuibban, AJ Meijer, MH Meisler, A Meléndez, TJ Melia, G Melino, MA Mena, JA Menendez, RF Menna-Barreto, MB Menon, FM Menzies, CA Mercer, A Merighi, DE Merry, S Meschini, CG Meyer, TF Meyer, CY Miao, JY Miao, PA Michels, C Michiels, D Mijaljica, A Milojkovic, S Minucci, C Miracco, CK Miranti, I Mitroulis, K Miyazawa, N Mizushima, B Mograbi, S Mohseni, X Molero, B Mollereau, F Mollinedo, T Momoi, I Monastyrska, MM Monick, MJ Monteiro, MN Moore, R Mora, K Moreau, PI Moreira, Y Moriyasu, J Moscat, S Mostowy, JC Mottram, T Motyl, CE Moussa, S Müller, S Muller, K Münger, C Münz, LO Murphy, ME Murphy, A Musarò, I Mysorekar, E Nagata, K Nagata, A Nahimana, U Nair, T Nakagawa, K Nakahira, H Nakano, H Nakatogawa, M Nanjundan, NI Naqvi, DP Narendra, M Narita, M Navarro, ST Nawrocki, TY Nazarko, A Nemchenko, MG Netea, TP Neufeld, PA Ney, IP Nezis, HP Nguyen, D Nie, I Nishino, C Nislow, RA Nixon, T Noda, AA Noegel, A Nogalska, S Noguchi, L Notterpek, I Novak, T Nozaki, N Nukina, T Nürnberger, B Nyfeler, K Obara, TD Oberley, S Oddo, M Ogawa, T Ohashi, K Okamoto, NL Oleinick, FJ Oliver, LJ Olsen, S Olsson, O Opota, TF Osborne, GK Ostrander, K Otsu, JH Ou, M Ouimet, M Overholtzer, B Ozpolat, P Paganetti, U Pagnini, N Pallet, GE Palmer, C Palumbo, T Pan, T Panaretakis, UB Pandey, Z Papackova, I Papassideri, I Paris, J Park, OK Park, JB Parys, KR Parzych, S Patschan, C Patterson, S Pattingre, JM Pawelek, J Peng, DH Perlmutter, I Perrotta, G Perry, S Pervaiz, M Peter, GJ Peters, M Petersen, G Petrovski, JM Phang, M Piacentini, P Pierre, V Pierrefite-Carle, G Pierron, R Pinkas-Kramarski, A Piras, N Piri, LC Platanias, S Pöggeler, M Poirot, A Poletti, C Poüs, M Pozuelo-Rubio, M Prætorius-Ibba, A Prasad, M Prescott, M Priault, N Produit-Zengaffinen, A Progulske-Fox, T Proikas-Cezanne, S Przedborski, K Przyklenk, R Puertollano, J Puyal, SB Qian, L Qin, ZH Qin, SE Quaggin, N Raben, H Rabinowich, SW Rabkin, I Rahman, A Rami, G Ramm, G Randall, F Randow, VA Rao, JC Rathmell, B Ravikumar, SK Ray, BH Reed, JC Reed, F Reggiori, A Régnier-Vigouroux, AS Reichert, JJ Reiners, RJ Reiter, J Ren, JL Revuelta, CJ Rhodes, K Ritis, E Rizzo, J Robbins, M Roberge, H Roca, MC Roccheri, S Rocchi, HP Rodemann, S Rodríguez de Córdoba, B Rohrer, IB Roninson, K Rosen, MM Rost-Roszkowska, M Rouis, KM Rouschop, F Rovetta, BP Rubin, DC Rubinsztein, K Ruckdeschel, EB Rucker, A Rudich, E Rudolf, N Ruiz-Opazo, R Russo, TE Rusten, KM Ryan, SW Ryter, DM Sabatini, J Sadoshima, T Saha, T Saitoh, H Sakagami, Y Sakai, GH Salekdeh, P Salomoni, PM Salvaterra, G Salvesen, R Salvioli, AM Sanchez, JA Sánchez-Alcázar, R Sánchez-Prieto, M Sandri, U Sankar, P Sansanwal, L Santambrogio, S Saran, S Sarkar, M Sarwal, C Sasakawa, A Sasnauskiene, M Sass, K Sato, M Sato, AH Schapira, M Scharl, HM Schätzl, W Scheper, S Schiaffino, C Schneider, ME Schneider, R Schneider-Stock, PV Schoenlein, DF Schorderet, C Schüller, GK Schwartz, L Scorrano, L Sealy, PO Seglen, J Segura-Aguilar, I Seiliez, O Seleverstov, C Sell, JB Seo, D Separovic, V Setaluri, T Setoguchi, C Settembre, JJ Shacka, M Shanmugam, IM Shapiro, E Shaulian, RJ Shaw, JH Shelhamer, HM Shen, WC Shen, ZH Sheng, Y Shi, K Shibuya, Y Shidoji, JJ Shieh, CM Shih, Y Shimada, S Shimizu, T Shintani, OS Shirihai, GC Shore, AA Sibirny, SB Sidhu, B Sikorska, EC Silva-Zacarin, A Simmons, AK Simon, HU Simon, C Simone, A Simonsen, DA Sinclair, R Singh, D Sinha, FA Sinicrope, A Sirko, PM Siu, E Sivridis, V Skop, VP Skulachev, RS Slack, SS Smaili, DR Smith, MS Soengas, T Soldati, X Song, AK Sood, TW Soong, F Sotgia, SA Spector, CD Spies, W Springer, SM Srinivasula, L Stefanis, JS Steffan, R Stendel, H Stenmark, A Stephanou, ST Stern, C Sternberg, B Stork, P Strålfors, CS Subauste, X Sui, D Sulzer, J Sun, SY Sun, ZJ Sun, JJ Sung, K Suzuki, T Suzuki, MS Swanson, C Swanton, ST Sweeney, LK Sy, G Szabadkai, I Tabas, H Taegtmeyer, M Tafani, K Takács-Vellai, Y Takano, K Takegawa, G Takemura, F Takeshita, NJ Talbot, KS Tan, K Tanaka, K Tanaka, D Tang, D Tang, I Tanida, BA Tannous, N Tavernarakis, GS Taylor, GA Taylor, JP Taylor, LS Terada, A Terman, G Tettamanti, K Thevissen, CB Thompson, A Thorburn, M Thumm, F Tian, Y Tian, G Tocchini-Valentini, AM Tolkovsky, Y Tomino, L Tönges, SA Tooze, C Tournier, J Tower, R Towns, V Trajkovic, LH Travassos, TF Tsai, MP Tschan, T Tsubata, A Tsung, B Turk, LS Turner, SC Tyagi, Y Uchiyama, T Ueno, M Umekawa, R Umemiya-Shirafuji, VK Unni, MI Vaccaro, EM Valente, G Van den Berghe, IJ van der Klei, W van Doorn, LF van Dyk, M van Egmond, LA van Grunsven, P Vandenabeele, WP Vandenberghe, I Vanhorebeek, EC Vaquero, G Velasco, T Vellai, JM Vicencio, RD Vierstra, M Vila, C Vindis, G Viola, MT Viscomi, OV Voitsekhovskaja, C von Haefen, M Votruba, K Wada, R Wade-Martins, CL Walker, CM Walsh, J Walter, XB Wan, A Wang, C Wang, D Wang, F Wang, F Wang, G Wang, H Wang, HG Wang, HD Wang, J Wang, K Wang, M Wang, RC Wang, X Wang, X Wang, YJ Wang, Y Wang, Z Wang, ZC Wang, Z Wang, DG Wansink, DM Ward, H Watada, SL Waters, P Webster, L Wei, CC Weihl, WA Weiss, SM Welford, LP Wen, CA Whitehouse, JL Whitton, AJ Whitworth, T Wileman, JW Wiley, S Wilkinson, D Willbold, RL Williams, PR Williamson, BG Wouters, C Wu, DC Wu, WK Wu, A Wyttenbach, RJ Xavier, Z Xi, P Xia, G Xiao, Z Xie, Z Xie, DZ Xu, J Xu, L Xu, X Xu, A Yamamoto, A Yamamoto, S Yamashina, M Yamashita, X Yan, M Yanagida, DS Yang, E Yang, JM Yang, SY Yang, W Yang, WY Yang, Z Yang, MC Yao, TP Yao, B Yeganeh, WL Yen, JJ Yin, XM Yin, OJ Yoo, G Yoon, SY Yoon, T Yorimitsu, Y Yoshikawa, T Yoshimori, K Yoshimoto, HJ You, RJ Youle, A Younes, L Yu, L Yu, SW Yu, WH Yu, ZM Yuan, Z Yue, CH Yun, M Yuzaki, O Zabirnyk, E Silva-Zacarin, D Zacks, E Zacksenhaus, N Zaffaroni, Z Zakeri, HJ Zeh, SO Zeitlin, H Zhang, HL Zhang, J Zhang, JP Zhang, L Zhang, L Zhang, MY Zhang, XD Zhang, M Zhao, YF Zhao, Y Zhao, ZJ Zhao, X Zheng, B Zhivotovsky, Q Zhong, CZ Zhou, C Zhu, WG Zhu, XF Zhu, X Zhu, Y Zhu, T Zoladek, WX Zong, A Zorzano, J Zschocke, B Zuckerbraun	04/01/2012
The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition. Cancer prevention research (Philadelphia, Pa.)	B Li, H Ren, P Yue, M Chen, FR Khuri, SY Sun	04/01/2012
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer biology & therapy	Y Li, S Fan, J Koo, P Yue, ZG Chen, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	03/01/2012
Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. The Journal of biological chemistry	Q Qi, K He, MH Yoo, CB Chan, X Liu, Z Zhang, JJ Olson, G Xiao, L Wang, H Mao, H Fu, H Tao, SS Ramalingam, SY Sun, PS Mischel, K Ye	02/24/2012
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling. The Journal of biological chemistry	YT Oh, P Yue, W Zhou, JM Balko, EP Black, TK Owonikoko, FR Khuri, SY Sun	01/02/2012
Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Molecular cancer therapeutics	Y Liu, SY Sun, TK Owonikoko, GL Sica, WJ Curran, FR Khuri, X Deng	01/01/2012
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Molecular cancer therapeutics	L Zhao, P Yue, S Lonial, FR Khuri, SY Sun	12/01/2011
Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer research	S Chen, W Cao, P Yue, C Hao, FR Khuri, SY Sun	10/01/2011
Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond. Cell cycle (Georgetown, Tex.)	C Li, SY Sun, FR Khuri, R Li	10/01/2011
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer biology & therapy	CX Xu, L Zhao, P Yue, G Fang, H Tao, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	09/15/2011
Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene	C Li, S Fan, TK Owonikoko, FR Khuri, SY Sun, R Li	09/01/2011
Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. Cancer research	L Dhandapani, P Yue, SS Ramalingam, FR Khuri, SY Sun	08/01/2011
Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Molecular cancer therapeutics	T Liu, R Yacoub, LD Taliaferro-Smith, SY Sun, TR Graham, R Dolan, C Lobo, M Tighiouart, L Yang, A Adams, RM O'Regan	08/01/2011
Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis. Molecular and cellular pharmacology	SY Sun	01/01/2011
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PloS one	CX Xu, Y Li, P Yue, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	01/01/2011
ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. The Journal of biological chemistry	YT Oh, X Liu, P Yue, S Kang, J Chen, J Taunton, FR Khuri, SY Sun	12/31/2010
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Molecular cancer	L Fu, YD Lin, HA Elrod, P Yue, Y Oh, B Li, H Tao, GZ Chen, DM Shin, FR Khuri, SY Sun	12/20/2010
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood	E David, JL Kaufman, CR Flowers, K Schafer-Hales, C Torre, J Chen, AI Marcus, SY Sun, LH Boise, S Lonial	12/09/2010
Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax. PloS one	Q Wang, SY Sun, F Khuri, WJ Curran, X Deng	10/14/2010
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia (New York, N.Y.)	Y Li, P Yue, X Deng, T Ueda, R Fukunaga, FR Khuri, SY Sun	10/01/2010
Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PloS one	HA Elrod, S Fan, S Muller, GZ Chen, L Pan, M Tighiouart, DM Shin, FR Khuri, SY Sun	08/16/2010
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer	SS Ramalingam, RD Harvey, N Saba, TK Owonikoko, J Kauh, DM Shin, SY Sun, S Strychor, M Tighiouart, MJ Egorin, H Fu, FR Khuri	08/15/2010
DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. Journal of cellular and molecular medicine	AC Bellail, MC Tse, JH Song, S Phuphanich, JJ Olson, SY Sun, C Hao	06/01/2010
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. The Journal of biological chemistry	C Li, S Chen, P Yue, X Deng, S Lonial, FR Khuri, SY Sun	05/21/2010
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PloS one	J Kauh, S Fan, M Xia, P Yue, L Yang, FR Khuri, SY Sun	04/28/2010
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia (New York, N.Y.)	S Fan, Y Li, P Yue, FR Khuri, SY Sun	04/01/2010
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. The Journal of clinical investigation	S Kang, S Elf, K Lythgoe, T Hitosugi, J Taunton, W Zhou, L Xiong, D Wang, S Muller, S Fan, SY Sun, AI Marcus, TL Gu, RD Polakiewicz, ZG Chen, FR Khuri, DM Shin, J Chen	04/01/2010
Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Molecular cancer	S Chen, L Fu, SM Raja, P Yue, FR Khuri, SY Sun	01/29/2010
Enhancing perifosine's anticancer efficacy by preventing autophagy. Autophagy	SY Sun	01/01/2010
N-acetylcysteine, reactive oxygen species and beyond. Cancer biology & therapy	SY Sun	01/01/2010
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer research	L Fu, YA Kim, X Wang, X Wu, P Yue, S Lonial, FR Khuri, SY Sun	12/01/2009
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'. Leukemia	RD Harvey, J Nettles, B Wang, SY Sun, S Lonial	11/01/2009
Enhancing mTOR-targeted cancer therapy. Expert opinion on therapeutic targets	X Wang, SY Sun	10/01/2009
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. Molecular cancer therapeutics	HA Elrod, P Yue, FR Khuri, SY Sun	09/01/2009
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. The Journal of biological chemistry	D Zhong, L Xiong, T Liu, X Liu, X Liu, J Chen, SY Sun, FR Khuri, Y Zong, Q Zhou, W Zhou	08/28/2009
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer biology & therapy	S Fan, SS Ramalingam, J Kauh, Z Xu, FR Khuri, SY Sun	08/01/2009
The role of cetuximab in the management of non-small-cell lung cancer. Clinical lung cancer	TK Owonikoko, SY Sun, SS Ramalingam	07/01/2009
Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Molecular biology of the cell	Z Liu, SM Oh, M Okada, X Liu, D Cheng, J Peng, DJ Brat, SY Sun, W Zhou, W Gu, K Ye	02/01/2009
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. Journal of receptor and signal transduction research	Y Du, Z Li, L Li, ZG Chen, SY Sun, P Chen, DM Shin, FR Khuri, H Fu	01/01/2009
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer biology & therapy	X Wang, N Hawk, P Yue, J Kauh, SS Ramalingam, H Fu, FR Khuri, SY Sun	12/01/2008
Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. British journal of cancer	H Zhang, L Su, S Müller, M Tighiouart, Z Xu, X Zhang, HJ Shin, J Hunt, SY Sun, DM Shin, ZG Chen	11/18/2008
Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Molecular cancer therapeutics	Y Lin, X Liu, P Yue, DM Benbrook, KD Berlin, FR Khuri, SY Sun	11/01/2008
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer research	W Zou, P Yue, FR Khuri, SY Sun	09/15/2008
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer research	X Wang, P Yue, YA Kim, H Fu, FR Khuri, SY Sun	09/15/2008
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer research	D Zhong, X Liu, FR Khuri, SY Sun, PM Vertino, W Zhou	09/15/2008
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Molecular pharmacology	AL Kasinski, Y Du, SL Thomas, J Zhao, SY Sun, FR Khuri, CY Wang, M Shoji, A Sun, JP Snyder, D Liotta, H Fu	09/01/2008
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clinical cancer research : an official journal of the American Association for Cancer Research	E David, R Sinha, J Chen, SY Sun, JL Kaufman, S Lonial	08/15/2008
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer research	YD Lin, S Chen, P Yue, W Zou, DM Benbrook, S Liu, TC Le, KD Berlin, FR Khuri, SY Sun	07/01/2008
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Molecular cancer therapeutics	SM Raja, S Chen, P Yue, TM Acker, B Lefkove, JL Arbiser, FR Khuri, SY Sun	07/01/2008
Gene expression profiling of non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands)	S Singhal, D Miller, S Ramalingam, SY Sun	06/01/2008
Therapeutic potential of synthetic triterpenoids in neuroblastoma. Cancer biology & therapy	SY Sun	05/01/2008
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Molecular cancer therapeutics	D Zhong, X Liu, K Schafer-Hales, AI Marcus, FR Khuri, SY Sun, W Zhou	04/01/2008
Modulation of death receptors by cancer therapeutic agents. Cancer biology & therapy	HA Elrod, SY Sun	02/01/2008
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proceedings of the National Academy of Sciences of the United States of America	Z Li, J Zhao, Y Du, HR Park, SY Sun, L Bernal-Mizrachi, A Aitken, FR Khuri, H Fu	01/08/2008
PPARgamma and Apoptosis in Cancer. PPAR research	HA Elrod, SY Sun	01/01/2008
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Molecular cancer therapeutics	HA Elrod, YD Lin, P Yue, X Wang, S Lonial, FR Khuri, SY Sun	07/01/2007
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer research	Y Qiu, X Liu, W Zou, P Yue, S Lonial, FR Khuri, SY Sun	05/15/2007
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer research	X Liu, P Yue, S Chen, L Hu, S Lonial, FR Khuri, SY Sun	05/15/2007
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood	E David, SY Sun, EK Waller, J Chen, FR Khuri, S Lonial	12/15/2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research	X Zhang, ZG Chen, MS Choe, Y Lin, SY Sun, HS Wieand, HJ Shin, A Chen, FR Khuri, DM Shin	09/01/2005

Awards

Dr. Sun is a recipient of numerous peer-reviewed grant awards including NIH/NCI R01, P01 and SPORE. Additionally, he is the recipient of the Georgia Cancer Coalition Distinguished Cancer Scholar (2003-2008). In 2015, he was named to the MilliPub Club, which recognizes current Emory faculty who have published one or more individual papers throughout their careers that have garnered more than 1,000 citations.